Adoption of immunotherapy in the community for patients diagnosed with metastatic melanoma.

Marieke J KrimphoveKarl H TullyDavid F FriedlanderMaya MarchesePraful RaviStuart R LipsitzKerry L KilbridgeAdam S KibelLuis A KluthPatrick A OttToni K ChoueiriQuoc Dien Trinh

Published in: Journal for immunotherapy of cancer (2019)

While the use of immunotherapy for metastatic melanoma has increased over time, adoption varies widely across hospitals. Underinsured patients were more likely to receive treatment at low immunotherapy prescribing hospitals. The variation suggests inequity in access to these potentially life-saving drugs.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
primary care
emergency department
electronic health record
replacement therapy